Received November 16, 2016; revised manuscript received June 3, 2017; accepted July 6, 2017; released online August 29, 2017 Time for primary review: 28 days Institute of Cardiovascular Research, Key Laboratory for Atherosclerology of Hunan Province (H.-P.C., D.G., Z.-W.Z., P.-P.H., X.-H.Y., C.H., L.-Y.C., W.X., M.Z., L.L., X.-D.X., X.-P.O., Y.-L.T., W.-D.Y., C.-K.T.), School of Pharmacy and Life Science College (X.Z., Z.-b.W.), Medical Research Center, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang, Hunan; Department of Cardiovascular Medicine, Second Affiliated Hospital of University of South China, Hengyang, Hunan (Q.Y., G.-P.T.), China; and Department of Biochemistry and Molecular Biology, Libin Cardiovascular Institute of Alberta, Cumming School of Medicine, University of Calgary, Health Sciences Center, 3330 Hospital Dr. NW, Calgary, Alberta (X.-L.Z.), Canada T2N4N1 The first three authors contributed equally to this work (H.-P.C., D.G., Z.-W.Z.).
